NCTN: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma (RTOG-1010)
Getting access
No access information recorded yet.
About this database
| Last updated | 2026-08-25 |
|---|
What exists, and how to get in.
No access information recorded yet.
| Last updated | 2026-08-25 |
|---|